In summary, despite showing negative results on key clinical measures, especially LVEF in patients with HFrEF, the β3-AR agonist remains a promising therapeutic option for the treatment of HF due to its beneficial effects on the other parameters such as increased cardiac index and improved cardiac performance as well as the favorable safety (Table 4). This evidence concerns the gene ADRB3 and hydrops fetalis.